Taken together, our findings suggest a role for xCT in the resistant phenotype and provide not only an additional potential predictive marker to be incorporated in a composite molecular signature for cisplatin resistance, but also a rational target for therapeutic interventions in patients with bladder cancer. The gene discussed is SLC7A11; the disease is urinary bladder carcinoma.